Opioid Use Disorder Pharmacotherapy

In one multidisciplinary inpatient model, patients who received team consultation had shorter hospital stays and lower 30-day readmission rates than those who did not. Pharmacy-based opioid use disorder programmes increased access to buprenorphine and supported treatment adherence. Every opioid use disorder treatment model involved pharmacy staff working within multidisciplinary teams alongside physicians, nurses, social workers, and community organisation staff. Pharmacy-based opioid use disorder models were generally low-barrier and included optional non-punitive urine drug screening in at least one programme. Buprenorphine was presented as a harm reduction tool for patients not aiming for abstinence and as part of low-threshold care.